These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 32503572)

  • 21. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
    Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS
    Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
    Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Jain N; O'Brien S; Thomas D; Kantarjian H
    Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
    Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
    [No Abstract]   [Full Text] [Related]  

  • 29. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.
    Brivio E; Bautista F; Zwaan CM
    Haematologica; 2024 Jun; 109(6):1700-1712. PubMed ID: 38832425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
    Ohana Z; Serraes S; Elder C; Katusa N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
    Curran E; O'Brien M
    Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
    Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
    Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
    Kantarjian H; Jabbour E
    Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
    Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
    Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
    Short NJ; Kantarjian H
    Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Gavralidis A; Brunner AM
    Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.